Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks

Rim Sekfali, Gérard Mimoun, Salomon Yves Cohen, Giuseppe Querques, Francesco Bandello, Riccardo Sacconi, Eric H. Souied, Vittorio Capuano

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate the efficacy of switching from intravitreal ranibizumab to intravitreal aflibercept in choroidal neovascularization secondary to angioid streaks. Design: Multicenter retrospective interventional case series. Methods: Patients previously treated with intravitreal ranibizumab with at least 12-month follow-up (M12) after switching (M0) to intravitreal aflibercept. Switch to intravitreal aflibercept was decided in cases of refractory or recurrent choroidal neovascularization. Primary endpoint: Change of best-corrected visual acuity using the Early Treatment Diabetic Retinopathy Study letters. Secondary endpoints: Mean change of central macular thickness, absence of intraretinal/subretinal fluid on spectral domain optical coherence tomography and the percentage of eyes with absence of leakage on fluorescein angiography. Results: Fourteen eyes of 13 patients were included. Mean best-corrected visual acuity was 65.0 ± 21.03 letters at M0 and 63.5 ± 17.30 letters at M12 (p = 0.5). Secondary endpoints: Mean central macular thickness was 344 ± 194.65 µm at M0 and 268 ± 79.97 µm at M12 (p = 0.008). Absence of intraretinal/subretinal fluid was observed in 71%. Fluorescein angiography (nine eyes) showed absence of leakage in 77% (seven eyes). Conclusion: Switching from intravitreal ranibizumab to intravitreal aflibercept represents a therapeutic option in patients with refractory or recurrent choroidal neovascularization secondary to angioid streaks.

Original languageEnglish
Pages (from-to)550-556
Number of pages7
JournalEuropean Journal of Ophthalmology
Volume30
Issue number3
DOIs
Publication statusPublished - May 1 2020

Keywords

  • Aflibercept
  • angioid streaks
  • anti-vascular endothelium growth factor therapy
  • choroidal neovascularization
  • fluorescein angiography
  • ranibizumab
  • spectral domain optical coherence tomography
  • switch

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks'. Together they form a unique fingerprint.

Cite this